Doc Gumshoe looks at the state of cancer treatment... and some of the interesting drug approvals from 2018
14 Comments Read MoreArticles
Looking Backward – And a Peek in the Other Direction
Friday File: Royalties, Scams, Buffett, and Gold
A hodgepodge of updates on the Real Money Portfolio and other stories of interest -- including thoughts on Alphabet, Berkshire, Boston Omaha, Cameco, Equinox, Franco-Nevada, Ligand, Momo, Okta, Omega Healthcare, Sandstorm and more...
10 Comments Read MoreWe use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
Just ran into this comment when looking for some info about Ligand that I had written -- not trying to pick on the Doc, ...
$CATALYSTS Yesterday I scanned the FDA Biopharm Catalyst website for additional catalysts not already in our Gummie Goo...
$ DOVA NP Dova Pharmaceuticals provides update on development strategy for Avatrombopag in Immune Thrombocytopeni...
$DOVA NPm: Dova Pharmaceuticals price target raised to $33 from $30 at Jefferies Jefferies analyst Eun Yang raise...
$DOVA Announces NDA Submission to FDA for Avatrombopag, a Second Generation Thrombopoietin Receptor Agonist https://glob...
Hi Joe and welcome to the Gummune. You may find a several posts about the $DOVA IPO at the following links by comment s...
Dova Pharmaceuticals will be debuting by IPO shortly, and this one's interesting. It's a play on avatrombopag, a second-...